Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan to Add Purchased Doses of Paxlovid, Xocova to Govt Stockpile
March 17, 2023
- Health Minister Vows to Make Use of Govt-Purchased Xocova
March 17, 2023
- Japan Damage Relief Panel Recognizes 11 More Deaths Possibly Tied to COVID Jabs
March 16, 2023
- PMDA Sets Target Duration of SaMD Priority Reviews to 6 Months in FY2024 Plan
March 14, 2023
- Japan Safety Panels Recognize 1st Death Tied to COVID Vaccine
March 13, 2023
- LDP Lawmakers Call on Local Governments to Urge HPV Vaccinations
March 13, 2023
- Japan to Offer COVID Drugs for Free until September-End
March 13, 2023
- Japan Eager to Resolve Lag in Pediatric Cancer Drug Development: Minister
March 10, 2023
- AbbVie’s Parkinson’s Drug, Kaken’s Eschar Remover Skip March Listing
March 9, 2023
- Chuikyo OKs Listing of Mounjaro, Libtayo, Imjudo; 30 Billion-Plus Peak Sales for Lilly Med
March 9, 2023
- Paxlovid Priced at 99,027 Yen per 5-Day Treatment; 5% Premium on Lagevrio Price
March 9, 2023
- Xocova Priced at 51,851 Yen per Course with Peak Sales Put at 19.2 Billion Yen
March 9, 2023
- Tagrisso Faces 10.5% Slash in June in Its Second Re-Pricing
March 9, 2023
- Emgality, Veklury, and More to Get Lower Prices in June: CEA Scheme
March 9, 2023
- LDP League Delivers Proposal on Health Coverage for Patches to Finance Minister
March 9, 2023
- Expert Narukawa Backs JPMA Pitch on Value-Based Pricing, but Disputes Blanket Price Maintenance for Patented Meds
March 8, 2023
- Japan Starts Omicron Vaccine Rollout for Ages 5-11
March 8, 2023
- Japan Panel OKs 2-Dose Regimen for Silgard 9 for Girls below Age 15
March 8, 2023
- AbbVie’s ADC Bags Sakigake Designation in Japan
March 8, 2023
- Japan Cabinet Approves Bill to Create “Japan CDC”
March 8, 2023
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…